Ivarmacitinib is safe and effective in moderate to severe ulcerative colitis

According to the recent study, ivarmacitinib is safe and effective in moderate to severe active ulcerative colitis. This study was published in the journal, Gastroenterology.

 The study was a randomized double blinded clinical study which included 164 patients with ulcerative colitis, who were randomized to receive oral ivarmacitinib 8 mg once daily (QD), 4 mg twice daily (BID), or 4 mg QD, or placebo for 8 weeks.

At the end of week 8, treatment response rate was higher in the 8mg QD (46.3%), 4mg BID (46.3%) and 4mg QD (43.9%) treatment group when compared with placebo group (26.8%). Clinical remission rate was improved in the three treatment groups 22.0%, 24.4%, and 24.4% respectively when compared with placebo group (4.9%).

Based on the results of the study, it is concluded that, ivarmacitinib is safe and effective providing new promising treatment in moderate to severe ulcerative colitis